Arning Erland, Bottiglieri Teodoro
Baylor Research Institute, Institute of Metabolic Disease, Dallas, TX, 75226, USA.
JIMD Rep. 2016;29:1-9. doi: 10.1007/8904_2014_336. Epub 2014 Sep 12.
The analysis of (6R)-5,6,7,8-tetrahydrobiopterin (BH4) and neopterin in cerebrospinal fluid (CSF) is often used to identify defects in the pterin biosynthetic pathway affecting monoamine metabolism that can lead to pediatric neurotransmitter diseases. Low levels of BH4 and neopterin alone may not be sufficient to determine the defect, and further testing is often required. We have developed a sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method for determination of BH4, 7,8-dihydrobiopterin (BH2), neopterin, and sepiapterin in CSF, which provides a more comprehensive evaluation of the pterin pathway. The method utilizes labeled stable isotopes as internal standards and allows for a fast 10-minute analysis by LC/MS/MS over a linear working range of 3 to 200 nmol/L. Total analytical imprecision is less than 14.4% for all pterin metabolites. Accuracy for BH4 and neopterin was determined by comparing data obtained by an alternative method using HPLC with EC and fluorescence detection. Excellent correlation was demonstrated for BH4 (r = 0.9646, 1/slope = 0.9397; n = 28; concentration range 3 to 63 nmol/L) and neopterin (r = 0.9919, 1/slope = 0.9539; n = 13; concentration range 5 to 240 nmol/L). CSF specimens from patients diagnosed with inborn errors of sepiapterin reductase (SR), 6-pyruvoyl-tetrahydropterin synthase (PTPS), dihydropteridine reductase (DHPR), and guanosine triphosphate cyclohydrolase (GTPCH) have been analyzed, and distinct pterin metabolite patterns were consistent with the initial diagnosis. This method differentiates patients with DHPR and SR deficiency from other pterin defects (GTPCH and PTPS) and will be useful for the diagnosis of specific defects in the pterin biosynthetic pathway.
脑脊液(CSF)中(6R)-5,6,7,8-四氢生物蝶呤(BH4)和新蝶呤的分析常用于识别影响单胺代谢的蝶呤生物合成途径缺陷,这些缺陷可导致儿童神经递质疾病。仅BH4和新蝶呤水平较低可能不足以确定缺陷,通常需要进一步检测。我们开发了一种灵敏的液相色谱串联质谱(LC-MS/MS)方法,用于测定脑脊液中的BH4、7,8-二氢生物蝶呤(BH2)、新蝶呤和蝶酰三酮,该方法能对蝶呤途径进行更全面的评估。该方法使用标记的稳定同位素作为内标,通过LC/MS/MS在3至200 nmol/L的线性工作范围内进行快速10分钟分析。所有蝶呤代谢物的总分析不精密度小于14.4%。通过比较使用高效液相色谱(HPLC)结合电化学和荧光检测的替代方法获得的数据,确定了BH4和新蝶呤的准确性。BH4(r = 0.9646,1/斜率 = 0.9397;n = 28;浓度范围3至63 nmol/L)和新蝶呤(r = 0.9919,1/斜率 = 0.9539;n = 13;浓度范围5至240 nmol/L)显示出极好的相关性。已对诊断为蝶酰三酮还原酶(SR)、6-丙酮酰四氢蝶呤合酶(PTPS)、二氢蝶啶还原酶(DHPR)和鸟苷三磷酸环化水解酶(GTPCH)先天性缺陷患者的脑脊液标本进行了分析,不同的蝶呤代谢物模式与初步诊断一致。该方法可将DHPR和SR缺乏患者与其他蝶呤缺陷(GTPCH和PTPS)区分开来,将有助于诊断蝶呤生物合成途径中的特定缺陷。